Boehringer Ingelheim Partners with Express Scripts on their Patient Assurance Program Expansion for People with Type 2 Diabetes
Boehringer Ingelheim is proud to announce its participation with Express Scripts to expand access to critical medicines for people with type 2 diabetes. Beginning July 1st, 2020, Express Scripts expanded their existing Patient Assurance Program, which was focused on insulin, to include DPP-4 inhibitors, GLP-1 agonists and SGLT-2 inhibitors providing people with type 2 diabetes increased access to these essential medications.
The expanded Express Scripts program provides an easy, automatic and seamless experience to eligible members, and may help increase access and adherence to critical diabetes medications by reducing out-of-pocket costs. The Patient Assurance Program caps member out-of-pocket costs at $25 per 30-day prescription for participating medications.
“We are pleased that the Boehringer Ingelheim and Lilly type 2 family of medicines will now be a part of Express Scripts’ expanded Patient Assurance Program, giving people greater access to guideline-based care and treatments for managing their condition at reduced and predictable out-of-pocket costs,” said Christine Marsh, senior vice president, market access at Boehringer Ingelheim. “This partnership is particularly important as diabetes affects nearly 10 percent of the U.S. population. It is an example of our commitment to help make our standard of care treatments affordable and accessible to those who need them, while aiming to improve health outcomes and reduce overall healthcare costs for those in the diabetes community.”
About Diabetes
Approximately 34.2 million Americans and an estimated 463 million adults worldwide have type 1 and type 2 diabetes. Type 2 diabetes is the most common form, accounting for an estimated 90 to 95 percent of all diagnosed adult diabetes cases in the U.S. Diabetes is a chronic condition that occurs when the body does not properly produce, or use, the hormone insulin.
About Boehringer Ingelheim Pharmaceuticals, Inc.
Boehringer Ingelheim Pharmaceuticals, Inc., based in Ridgefield, Conn., is the largest U.S. subsidiary of Boehringer Ingelheim Corporation.
Boehringer Ingelheim is one of the world’s top 20 pharmaceutical companies. Headquartered in Ingelheim, Germany, the company operates globally with approximately 50,000 employees. Since its founding in 1885, the company has remained family-owned, and today our goal is to improve the lives of humans and animals through its three business areas: human pharmaceuticals, animal health and biopharmaceutical contract manufacturing.
Boehringer Ingelheim concentrates on developing innovative therapies that can improve and extend patients’ lives. As a research-driven pharmaceutical company, it plans in generations for long-term success. Its research efforts are focused on diseases with high, unmet medical need. In animal health, the company stands for advanced prevention.
In 2018, Boehringer Ingelheim achieved net sales of around $20.7 billion (17.5 billion euros). R&D expenditure of almost $3.7 billion (3.2 billion euros) corresponded to 18.1 percent of net sales.
Boehringer Ingelheim is committed to improving lives and strengthening our communities. Please visit www.boehringer-ingelheim.us/csr to learn more about Corporate Social Responsibility initiatives.
For more information, please visit www.boehringer-ingelheim.us, or follow us on Twitter @BoehringerUS.